Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders

A method for treating a disorder associated with the S1P1 receptor in an individual comprising administering to said individual in need thereof a therapeutically effective amount of a compound selected from compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates and hydrates thereof:

• wherein:
• m is 1;
• n is 1 or 2;
• Y is N or CR1;
• Z is N or CR4;
• R1, R2, and R4 are each independently selected from the group consisting of H, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 alkylamino, C1-C6 alkylsulfonyl, C1-C6 alkylthio, carboxamide, cyano, C3-C7 cycloalkoxy, C3-C7 cycloalkyl, C1-C6 haloalkoxy, C1-C6 haloalkyl, halogen, heteroaryl and heterocyclyl, wherein said C1-C6 alkyl and C1-C6 alkoxy are each optionally substituted with one or two substituents selected from C3-C7 cycloalkyl and halogen;
• and
• R3 is C3-C7 cycloalkyl;
• wherein said disorder associated with the S1P1 receptor is selected from the group consisting of:
• psoriasis, rheumatoid arthritis, acne, psoriatic arthritis, inflammatory bowel disease, Crohn's disease, transplant rejection, multiple sclerosis, biliary cirrhosis, systemic lupus erythematosus, ulcerative colitis, and type I diabetes.